Parkinson's Disease clinical trials in Arizona
18 active Parkinson's Disease trials with a site in Arizona. Describe your situation to see which ones look like a fit.
- Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease
- A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
- A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- A Study of Buntanetap in Participants With PD
- TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD
- A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications
- Parkinson's Foundation PD GENEration Genetic Registry
- PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
- Abbott DBS Post-Market Study of Outcomes for Indications Over Time
- Deep Brain Stimulation (DBS) Retrospective Outcomes Study
- Deep Brain Stimulation (DBS) of the Pedunculopontine Nucleus (PPN)
- Phase 1/2a Study of ANPD001 in Parkinson Disease
- A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.